Investor Contacts:Tetraphase PharmaceuticalsTeri Dahlman617email@example.comArgot PartnersMaeve Conneighton212firstname.lastname@example.orgMedia Contact:Sam Brown Inc.Mike Beyer312email@example.com
WATERTOWN, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 3:00 p.m. Eastern Time at the Lotte New York Palace Hotel in New York City. A live audio webcast of the Stifel presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days. About Tetraphase Pharmaceuticals, Inc.Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.